Ublituximab
Chronic Lymphocytic Leukemia (CLL) & Non-Hodgkin's Lymphoma
Phase 3Development paused/completed (historical program)
Key Facts
Indication
Chronic Lymphocytic Leukemia (CLL) & Non-Hodgkin's Lymphoma
Phase
Phase 3
Status
Development paused/completed (historical program)
Company
About TG Therapeutics
TG Therapeutics is a publicly traded biopharmaceutical company dedicated to advancing innovative therapies for patients with B-cell-mediated diseases. Its primary achievement is the FDA approval and commercialization of BRIUMVI® (ublituximab) for relapsing multiple sclerosis, a significant milestone that has transitioned the company to a commercial entity. The company's strategic direction involves maximizing the commercial potential of BRIUMVI, expanding its label, and advancing its pipeline in oncology and autoimmune indications. TG Therapeutics operates with a focused mission to leverage scientific advances to develop superior treatment options.
View full company profile